Data on shingles candidate vaccine presented at ID Week conference

New data on shingles candidate vaccine Shingrix was presented at the Infectious Disease Week (ID Week) scientific conference in New Orleans, USA, this week. The data on Shingrix, which is being developed by GSK, examined co-administration of it with the flu vaccine, a flexible dosing schedule and the vaccine’s impact on quality of life. Shingles typically presents as a painful, itchy rash that develops on one side of the body as a result of reactivation of latent chickenpox virus (varicella zoster virus or VZV). Data from many countries indicates that more than 90% of adults have been infected with varicella